אביטרקסט טבע

Nchi: Israeli

Lugha: Kiebrania

Chanzo: Ministry of Health

Viambatanisho vya kazi:

METHOTREXATE

Inapatikana kutoka:

ABIC MARKETING LTD, ISRAEL

ATC kanuni:

L01BA01

Dawa fomu:

תמיסה להזרקה

Tungo:

METHOTREXATE 25 MG/ML

Njia ya uendeshaji:

תוך-שרירי, תוך-ורידי, תוך-שדרתי, תוך-עורקי, תוך חדרי

Dawa ya aina:

מרשם נדרש

Viwandani na:

PHARMACHEMIE B.V., (TEVA GROUP) ,THE NETHERLANDS

Kundi la matibabu:

METHOTREXATE

Eneo la matibabu:

METHOTREXATE

Matibabu dalili:

Antineoplastic chemotherapy: treatment of gestational choriocarcinoma, chorioadenoma destruents and hydatidiform mole. Palliation of acute lymphocytic leukemia. Abitrexate is also indicated in the treatment and prophylaxis of meningeal leukemia. Greatest effect has been observed in palliation of acute lymphoblastic (stem cell) leukemias in children. In combination with other anticancer agents, Abitrexate may be used for the induction of remission, but is most commonly used in maintenance of induced remissions. Abitrexate may be used alone or in combination with other antineoplastics in the management of breast cancer, epidermoid cancers of the head and neck, lung cancer (particularly squamous cell and small cell types), bladder cancer and osteogenic cancer. Abitrexate is effective in the treatment of the advanced stages (III and IV Peter's Staging System) of lymphosarcoma, particularly in children, and in advanced cases of mycosis fungoides. Psoriasis: because of the high risk attending its use, Abitrexate is

Idhini ya tarehe:

2015-02-28